Trials / Recruiting
RecruitingNCT05836948
The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors
An Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-9839 for Injection in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 174 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, phase I clinical trial of SHR-9839 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-9839 | Weekly fixed dose injection of SHR-9839 |
Timeline
- Start date
- 2023-05-18
- Primary completion
- 2026-05-01
- Completion
- 2026-06-01
- First posted
- 2023-05-01
- Last updated
- 2025-08-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05836948. Inclusion in this directory is not an endorsement.